Investors showed strong interest in the Gujarat Kidney and Super Specialty IPO, which closed with more than five times the shares on offer.
The IPO was subscribed 5.21 times overall. Break‑down by investor type:
Current grey‑market premium (GMP) is about 2.2%, or roughly Rs 2.5 above the upper price band of Rs 114. This points to an expected listing price near Rs 116‑117 per share.
Gujarat Kidney runs seven multi‑speciality hospitals and four pharmacies in central Gujarat, focusing on renal care and other super‑speciality services. It has 490 beds (340 occupied) and a staff of around 720, including 89 doctors.
For FY 2025, the company reported:
The IPO is priced at Rs 108‑114 per share, giving a pre‑issue P/E multiple of about 61.6× at the top of the band. This is higher than peers such as Yatharth Hospital, GPT Healthcare and KMC Specialty Hospitals, which trade at much lower multiples.
Funds will mainly go to expansion, including:
Some brokers suggest caution because the valuation is aggressive and the company’s size makes execution riskier. They recommend that conservative investors wait for post‑listing price discovery before taking a position.
While the IPO attracted strong demand, especially from retail investors, the high P/E multiple and ambitious growth plans mean investors should weigh the upside against valuation and execution risks.
This summary is for informational purposes only and does not constitute investment advice. Do your own research before making any decisions.
Download the TradeKaizen app to practice F&O trading with real-time market data anytime, anywhere.
Get it on Google PlayConnect with fellow traders, share strategies, and improve your trading skills in our Telegram group.
Join TelegramPrism, the holding company behind Oyo, received a strong go‑ahead from its shareholders to raise up to ₹6,650 crore through a fresh equity IPO. Shareholder vote clears the path At an Extraordinary General Meeting on December 20, 2025, shareholders approved the IPO plan and a bonus‑share issue, with an overwhelming majority supporting both resolutions. Details of the offering Target raise: up to ₹6,650 crore via new equity shares. Bonus issue: 1 fully paid‑up share for every 19 existing shares. Record date for bonus eligibility: 5 December 2025. Final decision pending regulatory clearances and market conditions. Financial backdrop Moody’s reaffirmed Prism’s corporate family rating, expecting EBITDA to more than double to about $280 million (≈₹2,496 crore) in FY 2026, driven by premium storefront expansion and cost efficiencies. Oyo reported a profit after tax of over ₹200 crore in Q1 FY 2026, up from ₹87 crore a year earlier. Revenue grew 47% to ₹2,019 crore, and gross booking value surged 144% to ₹7,227 crore, helped by new hotel openings and strong performance of premium brands. What this means for investors The approved IPO and bonus shares give existing Oyo shareholders a chance to increase their stake at a potentially attractive price, while the company’s improving earnings and expansion plans could drive future share value. Remember, this is perspective, not a prediction. Do your own research before making any investment decisions.
India's market regulator has given the green light to three fresh public offerings, covering cloud services, polymer manufacturing and infrastructure construction. ESDS Software Solution – Cloud Infrastructure ESDS plans to raise up to ₹600 crore by issuing new shares. All money will stay with the company; there is no sell‑off by existing owners. Potential pre‑IPO placement of up to ₹120 crore could lower the fresh issue size. About ₹480.7 crore will fund new cloud‑computing equipment and data‑centre upgrades. The remaining amount will support general corporate needs. BLS Polymers – Custom Polymer Compounds BLS Polymers seeks to raise ₹69.84 crore from a fresh issue of 1.7 crore equity shares. Funds will expand existing manufacturing capacity. ₹75 crore allocated for working‑capital requirements. Any surplus will go to general corporate purposes. The company's products are used in cables, power lines, telecom networks and pipeline coatings, tying its growth to infrastructure spending. Dhariwal Buildtech – Roads, Bridges & Tunnels Dhariwal Buildtech aims to raise ₹950 crore through a fresh share issue. ₹174.2 crore will repay its own borrowings. ₹300 crore will clear debt of its subsidiaries. Remaining funds will support ongoing construction projects. The firm focuses on highways, bridges, tunnels and rural infrastructure across Haryana and beyond. With these approvals, the companies are moving closer to launching their IPOs, adding fresh opportunities for investors and testing market demand in the months ahead. Remember, this is just an overview, not investment advice. Do your own research before making any decisions.
Tonbo Imaging, a leading Indian defence technology company, has filed its IPO prospectus and is putting 18 million shares up for sale. What the IPO Involves Tonbo Imaging has filed a draft red‑herring prospectus with SEBI. The company is not raising new money; it is selling existing shares. Total shares offered: 18,085,246 Face value: Rs 2 per share Shares from promoters: 1,960,000 Shares from promoter group: 339,700 Shares from other investors: 15,635,046 Company Background Founded as a sensor and imaging specialist, Tonbo switched to defence products after a promoter buyout in 2012. It now makes thermal imagers, weapon sights, missile seekers and other smart battlefield gear. Growth Highlights Fastest‑growing defence tech firm in India (FY23‑FY25) by revenue and profit margins. Largest Indian exporter of thermal imaging systems, accounting for about 93% of the country’s exports in FY25. Products used by militaries, police and security agencies in 24 countries. Financial Snapshot (FY25) Revenue: Rs 469.08 crore, with Europe contributing over 65%. Profit after tax: Rs 72.76 crore (PAT margin >15%). Order book: Rs 266.57 crore, plus new orders worth Rs 71.68 crore in Oct‑Nov 2025. Why It Matters to Investors The share sale gives current shareholders a way to cash out, while the company’s strong export growth and solid order pipeline could support the share price. Retail investors get a chance to own a piece of a company that is expanding rapidly in the global defence market. Disclaimer Remember, this is just an overview, not a recommendation. Do your own research and consider your risk tolerance before investing.